As research has progressed, the use of biologics (anti-TNF-a) and stem cell therapies has substantially improved CD treatment [7–9], but anti-TNF therapy may increase the risk for serious and opportunistic infections in patients, and stem cell therapies are expensive and limited by the challenges of stem cell transport [10, 11]. This evidence concerns the gene TNF and Opportunistic infection.